Angela Antipin
Family Medicine · Kernersville, NCNPI 1265726244
Payments from drug & device makers
Across 478 payments — averaging $16.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- AbbVie$863
- Lilly USA, LLC$850
- Novo Nordisk$838
- Mannkind Corporation$629
- Amgen$394
- plus $2K from 17 others
What the payments were for
- Food & beverage$7,81999%
- Education$461%
- Gifts$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 121 | $2,074 |
| AbbVie(2 entities) | 54 | $863 |
| Lilly USA, LLC | 55 | $850 |
| Novo Nordisk | 49 | $838 |
| Mannkind Corporation | 50 | $629 |
| Amgen(2 entities) | 25 | $394 |
| Boehringer Ingelheim | 21 | $385 |
| Johnson & Johnson | 16 | $308 |
| Merck | 19 | $308 |
| GSK | 15 | $255 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 14 | $232 |
| Sanofi-aventis U.S. LLC | 10 | $205 |
| Pfizer | 8 | $136 |
| Avanir Pharmaceuticals, Inc. | 6 | $122 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $64 |
| Dexcom, Inc. | 2 | $63 |
| Otsuka America Pharmaceutical, Inc. | 2 | $46 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $44 |
| Abbott | 2 | $31 |
| Biohaven Pharmaceuticals, Inc. | 1 | $23 |
| Exact Sciences | 1 | $22 |
| Astellas Pharma US Inc | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$105
How this compares
$7,925 in reported general payments places this provider in the 90th percentile of 3,444 family medicine providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 36 | $35,034 |
| Tresiba Flextouch U-100Insulin Degludec | 16 | $32,547 |
| TrulicityDulaglutide | 33 | $29,711 |
| EliquisApixaban | 39 | $26,082 |
| MounjaroTirzepatide | 24 | $25,467 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 39 | $25,125 |
| Tresiba Flextouch U-200Insulin Degludec | 17 | $17,890 |
| JanuviaSitagliptin Phosphate | 15 | $17,648 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 20 | $17,595 |
| JardianceEmpagliflozin | 22 | $16,825 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 12 | $15,381 |
| FarxigaDapagliflozin Propanediol | 19 | $13,092 |
| Xigduo XrDapaglifloz Propaned/Metformin | 12 | $9,645 |
| LinzessLinaclotide | 14 | $8,524 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $3,204 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $850 | $55,17857 claims |
| Novo NordiskOzempic | $838 | $35,03436 claims |
| AstraZenecaBreztri Aerosphere, Farxiga | $2,074 | $30,68739 claims |
| PfizerEliquis | $136 | $26,08239 claims |
| GSKTrelegy Ellipta | $255 | $25,12539 claims |
| MerckJanuvia | $308 | $17,64815 claims |
| Boehringer IngelheimJardiance | $385 | $16,82522 claims |
| AbbVieLinzess | $863 | $8,52414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,444 family medicine providers in North Carolina.
Other family medicine in Kernersville
- Barton WilliamsWilmington$17.3M
- Alexander MurrayGreensboro$13M
- Arin PiramzadianJacksonville$13M
- Jonathan WilsonHickory$12.7M
- George RaadCharlotte$7.7M
- Cecil FarringtonSalisbury$6.4M
- Christian MartinShelby$5.4M
- John EarlHickory$4.7M
- Patrick MorganteHavelock$4.6M
- Stephen JonesShelby$4.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.